A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
This study looks at a new medicine called **BMS-986393** to see if it's safe and works well for people with a type of blood cancer called *multiple myeloma* (MM) that has come back or won't go away, known as *relapsed* and/or *refractory multiple myeloma (RRMM)*. The study will try to find out the best dose of BMS-986393 when used with other medicines like alnuctamab, mezigdomide, and iberdomide. To join, participants should have had MM treatments before, and their overall health should be stable. People cannot join if they have other health issues that might affect study results or have problems with the brain and nerves from MM.
- 🔍 **Key Points**: Study needs several visits to check health and treatment effects.
- đź’Š Participants receive new treatment combinations.
- ⚠️ Some risks may include side effects from new medicines.
Study details
NCT06121843
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
11 July 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.